Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Appoints Chairman

NEW YORK, Aug. 17 – Rubicon Genomics named Ernest Ludy chairman of the board while also electing Roger Newton to the board of directors, the company announced earlier this week.

Ann Arbor, Mich.-based Rubicon specializes in developing alternatives to PCR for amplifying DNA sequences and identifying SNPs. The company's technology, called OmniPlex, involves reformatting chromosomes into new molecules called plexisomes that are more easily amplified and manipulated, according to the company.

"I look forward to helping the company achieve its goal to make personalized medicine a clinical reality," Ludy said in a statement.

Ludy was founder and former CEO of The Medstat Group, a publicly-traded health care information company acquired by the Thomson Corporation in 1994 for $341 million.

Roger Newton, currently CEO of HDL-targeted therapies company Esperion Therapeutics, formerly served as chairman of the atherosclerosis drug discover team at Parke-Davis, since merged with Pfizer.

In June, Rubicon named Thomas Collet CEO. Until Collet joined the company, John Langmore, a co-founder of Rubicon Genomics on leave from the biophysics department of the University of Michigan in Ann Arbor, served as acting CEO. Langmore founded the company in 1998 along with Vladimir Makarov, a scientist formerly with the Engelhardt Institute of Molecular Biology in Moscow.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.